Neutralizing antibody to FGFR2 can act as a selective biomarker and potential therapeutic agent for gastric cancer with FGFR2 amplification

Fibroblast growth factor receptor 2 (FGFR2) amplification has been reported in 5-10% of gastric cancer (GC) and is associated with poor prognosis. In this study, we characterized the anti-tumor effect of PRO-007, a newly developed recombinant monoclonal antibody that targets FGFR2, in GC cell lines...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Am J Transl Res
Main Authors: Kim, Seung Tae, Lee, In Kyoung, Rom, Eran, Sirkis, Roy, Park, Se Hoon, Park, Joon Oh, Park, Young Suk, Lim, Ho Yeong, Kang, Won Ki, Kim, Kyoung-Mee, Yayon, Avner, Lee, Jeeyun
Formato: Artigo
Idioma:Inglês
Publicado em: e-Century Publishing Corporation 2019
Assuntos:
Original Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6684926/
https://ncbi.nlm.nih.gov/pubmed/31396354
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados